NSC47924 是一种 37/67kDa 层粘连蛋白受体 (LR) 抑制剂(IC50 值为 58.9 μM),通过抑制 RPSA 下调过度激活的 Akt/mTOR 信号轴,从而刺激自噬 (autophagy) 通路并修复受损的线粒体自噬 (Mitophagy) 过程,同时可有效阻断由 67LR 介导的肿瘤细胞与基底膜的粘附,进而抑制癌细胞的迁移和侵袭,并通过促使 37/67 kDa LR 内化和降解、同时将 PrPC “困”在细胞表面而具有潜在的抗朊病毒活性,可用于朊病毒病、阿尔茨海默病及侵袭性/转移性恶性肿瘤的相关研究。
产品编号: MS-F74045 纯度: 95.0% CAS No.: 6638-24-0 分子式: C18H17NO2 分子量: 279.33
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

NSC47924 是一种 37/67kDa 层粘连蛋白受体 (LR) 抑制剂(IC50 值为 58.9 μM),通过抑制 RPSA 下调过度激活的 Akt/mTOR 信号轴,从而刺激自噬 (autophagy) 通路并修复受损的线粒体自噬 (Mitophagy) 过程,同时可有效阻断由 67LR 介导的肿瘤细胞与基底膜的粘附,进而抑制癌细胞的迁移和侵袭,并通过促使 37/67 kDa LR 内化和降解、同时将 PrPC “困”在细胞表面而具有潜在的抗朊病毒活性,可用于朊病毒病、阿尔茨海默病及侵袭性/转移性恶性肿瘤的相关研究。

生物实验数据

生物活性 NSC47924 is a 37/67 kDa laminin receptor (LR) inhibitor with an IC50 value of 58.9 μM that inhibits RPSA to downregulate the hyperactivated Akt/mTOR signaling axis, thereby stimulating the autophagy pathway and restoring impaired mitophagy, effectively blocks 67LR-mediated adhesion of tumor cells to the basement membrane to suppress cancer cell migration and invasion, and exhibits potential anti-prion activity by promoting the internalization and degradation of the 37/67 kDa LR while trapping PrPC on the cell surface, making it suitable for research on prion diseases, Alzheimer's disease, and aggressive/metastatic malignancies.
体外研究
(In Vitro)

NSC47924 (50-200 μM; 1 h) 在无细胞 ELISA 实验中可强效抑制人重组 37LRP 与人重组 PrP 的直接结合。
NSC47924 (20 μM; 30-180 min) 可在活的 GT1 和 HEK-293-LR 细胞中破坏 37/67 kDa LR 与 PrPC 之间的相互作用,降低其免疫复合物中 67 kDa LR 的水平并提高 PrPC 的水平。
NSC47924 (20 μM; 30-180 min) 可在活 GT1 细胞中诱导 37/67 kDa LR 的细胞表面水平呈时间依赖性降低,并稳定细胞表面 PrPC。
NSC47924 (20 μM; 30-180 min) 可诱导活 GT1 细胞中 37/67 kDa LR 的内吞,并消除其与 PrPC 的共定位。
NSC47924 (20 μM; 30-180 min) 可诱导活 GT1 细胞内的 37/67 kDa LR 在内溶酶体中进行性积累,在 180 min 时观察到最大程度的共定位。
NSC47924 (20 μM; 30 min) 可诱导活 GT1 细胞中的 LR 内吞至早期内体中。
NSC47924 (20 μM; 30-180 min) 可促进活 GT1 细胞中 LR 的溶酶体介导降解。
NSC47924 (20 μM; 3-24 h) 可抑制家族性阿尔茨海默病 (fAD) 成纤维细胞 (APPV717I、PS1M146L) 和散发性阿尔茨海默病 (unAD) 成纤维细胞中过度激活的 Akt-mTOR 通路,且在 24 h 时观察到 mTOR 磷酸化的抑制作用达到峰值。
NSC47924 (20 μM; 3-24 h) 可刺激并恢复家族性阿尔茨海默病 (fAD) 成纤维细胞 (APPV717I、PS1M146L) 和散发性阿尔茨海默病 (unAD) 成纤维细胞中的自噬流,这一点可通过 LC3-II 周转率升高以及 LC3 降解速率恢复正常得到证明。
NSC47924 (20 μM; 24 h) 可通过 TFEB 核转位及自噬相关基因表达上调,促进家族性阿尔茨海默病 (APPV717I, PS1M146L) 成纤维细胞的自噬。
NSC47924 (20 μM; 24 h) 可恢复线粒体网络形态并诱导家族性阿尔茨海默病 (fAD) 成纤维细胞 (APPV717I, PS1M146L) 发生线粒体自噬,从而促进受损线粒体的清除。
NSC47924 (20 μM; 3-24 h) 可使家族性阿尔茨海默病 (fAD) 成纤维细胞 (APPV717I、PS1M146L) 中 PINK1 和 Parkin 蛋白的周转恢复正常,并重建线粒体质量控制。
NSC47924 (20 μM; 24 h) 可增强家族性阿尔茨海默病 (APPV717I、PS1M146L) 成纤维细胞中 p62 和 NDP52 的溶酶体降解,以及 OPTN 的蛋白酶体降解,这支持了线粒体自噬的激活。
NSC47924 (20 μM; 24 h) 可改善家族性阿尔茨海默病 (fAD) 成纤维细胞 (APPV717I, PS1M146L) 的线粒体呼吸功能并降低氧化应激,而对散发性阿尔茨海默病 (unAD) 成纤维细胞无显著影响。
NSC47924 可选择性且呈剂量依赖性地抑制 LR-293 细胞对层粘连蛋白的粘附,其 IC50 为 19.35 μM、Ki 为 2.45 μM,且不会影响细胞与其他细胞外基质蛋白的黏附。
NSC47924 (20 μM) 可特异性抑制由 67LR 介导的 LR-293 细胞向层粘连蛋白的迁移以及对 Matrigel 的侵袭,但对低表达 67LR 的 V-293 细胞无影响。

Western Blot Analysis

Cell Line: GT1 cells
Concentration: 20 μM
Incubation Time: 30 min, 90 min, 180 min at 37°C
Result: Caused a time-dependent decrease in both 37 kDa LRP and 67 kDa LR isoforms on the cell surface, while stabilizing PrP^C levels on the plasma membrane.

Immunofluorescence

Cell Line: GT1 cells
Concentration: 20 μM
Incubation Time: 30 min, 90 min, 180 min at 37°C
Result: Induced internalization of 37/67 kDa LR, with reduced colocalization between 37/67 kDa LR and PrP^C that was abolished by 90 and 180 min of treatment.
Showed sparse, reduced-intensity punctate staining of 37/67 kDa LR intracellularly compared to controls.\nCaused time-dependent colocalization of 37/67 kDa LR with Lamp1 (endo-lysosome marker), with a Pearson’s Correlation Coefficient average value higher than 0.7 at 90 min and 0.8 at 180 min, indicating progressive accumulation in endo-lysosomes.

Immunofluorescence

Cell Line: GT1 cells
Concentration: 20 μM
Incubation Time: 30 min at 37°C
Result: Caused 37/67 kDa LR to colocalize with EEA1 (early endosome marker), with a Pearson’s Correlation Coefficient average value higher than 0.6, indicating accumulation in early endosomes.

Western Blot Analysis

Cell Line: GT1 cells
Concentration: 20 μM
Incubation Time: 30 min, 180 min at 37°C
Result: Induced generation of 37/67 kDa LR fragments, which was inhibited by co-treatment with NH4Cl, resulting in accumulation of full-length 37/67 kDa LR.

Western Blot Analysis

Cell Line: unaffected control subject (unAD) fibroblasts, familial Alzheimer's disease (fAD) fibroblasts with APP V717I or PS1 M146L mutations
Concentration: 20 μM
Incubation Time: 3 h, 24 h
Result: Induced a decrease in Akt phosphorylation (Ser473) levels in both unAD and fAD fibroblasts compared to untreated controls.
Downregulated mTOR phosphorylation (Ser2448) in a time-dependent manner, with a significant inhibitory effect observed at 3 h and a remarkable reduction after 24 h in both unAD and fAD cell lines.
Progressively reduced phosphorylation of the mTOR downstream effectors 4E-BP1 (Ser65) and rpS6 (Ser235/236) over time, with a notable decrease at 24 h in fAD fibroblasts.

Cell Autophagy Assay

Cell Line: unaffected control subject (unAD) fibroblasts, familial Alzheimer's disease (fAD) fibroblasts with APP V717I or PS1 M146L mutations
Concentration: 20 μM; 20 μM plus 50 μM chloroquine (CQ)
Incubation Time: 3 h, 24 h (20 μM alone); 24 h (20 μM plus CQ)
Result: Caused a significant accumulation of LC3-II after 3 h, followed by a significant decrease after 24 h in unAD fibroblasts.
Resulted in a significant increase in LC3-II levels when combined with CQ compared to single treatments in unAD fibroblasts.
Increased LC3-II levels at 3 h, followed by a decrease at 24 h in fAD fibroblasts; combined treatment with CQ further increased LC3-II levels in fAD fibroblasts.
Reduced the number of LC3-positive dots and increased their size in both unAD and fAD fibroblasts; combined treatment with CQ significantly increased LC3-dots number (but not size) compared to NSC47924 alone.
Restored the impaired LC3 degradation rate in fAD fibroblasts, aligning it closer to unAD levels after 24 h.

Real Time qPCR

Cell Line: unaffected control subject (unAD) fibroblasts, familial Alzheimer's disease (fAD) fibroblasts with APP V717I or PS1 M146L mutations
Concentration: 20 μM
Incubation Time: 24 h
Result: Increased nuclear TFEB accumulation in both unAD and fAD fibroblasts compared to untreated controls.
Significantly upregulated the mRNA expression levels of autophagy-linked genes ULK1, BECN1, PIK3C3, LC3, and p62 in fAD fibroblasts compared to untreated controls.

Immunofluorescence

Cell Line: unaffected control subject (unAD) fibroblasts, familial Alzheimer's disease (fAD) fibroblasts with APP V717I or PS1 M146L mutations
Concentration: 20 μM; 20 μM plus 50 μM chloroquine (CQ)
Incubation Time: 24 h
Result: Restored the tubular mitochondrial network morphology in fAD fibroblasts, reducing the number of TOM20-positive objects and increasing their mean volume compared to untreated fAD controls.
Resulted in a marked colocalization between LC3 and TOM20 when combined with CQ, with higher Pearson correlation coefficients in fAD fibroblasts than in unAD fibroblasts.
Decreased TOM20 protein levels in fAD fibroblasts compared to untreated controls, indicating enhanced mitophagic clearance.

Western Blot Analysis

Cell Line: unaffected control subject (unAD) fibroblasts, familial Alzheimer's disease (fAD) fibroblasts with APP V717I or PS1 M146L mutations
Concentration: 20 μM
Incubation Time: 3 h, 6 h, 24 h
Result: Caused a time-dependent decrease in full-length PINK1 (f-PINK1) protein levels in both unAD and fAD fibroblasts, with a significant reduction observed after 24 h.
Increased PINK1 cleavage rate accompanied by decreased f-PINK1 levels in fAD fibroblasts.
Decreased Parkin protein levels over time in fAD fibroblasts, with a significant reduction after 24 h.
Reduced Parkin mitochondrial localization in fAD fibroblasts, restoring a distribution resembling unAD fibroblasts.
Enhanced the lysosomal degradation of phospho-Ub (Ser65) proteins in fAD fibroblasts.

Western Blot Analysis

Cell Line: familial Alzheimer's disease (fAD) fibroblasts with APP V717I or PS1 M146L mutations
Concentration: 20 μM; 20 μM plus 100 nM bafilomycin A1 (Baf.); 20 μM plus 100 μM ALLN
Incubation Time: 3 h, 24 h
Result: Increased p62 and NDP52 protein levels in fAD fibroblasts compared to untreated controls; combined treatment with Baf.
further amplified their accumulation, indicating enhanced delivery to lysosomes.
Reduced OPTN protein levels in fAD fibroblasts, and this reduction was not rescued by Baf.
but was rescued by the proteasome inhibitor ALLN, indicating proteasomal-mediated degradation of OPTN.
Progressively increased phospho-TBK1 (Ser172) levels over time up to 24 h in fAD fibroblasts, while decreasing phospho-OPTN (Ser177) levels.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 279.33
分子式 C18H17NO2
CAS No. 6638-24-0

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础